RemSleep FDA-cleared DeltaWave but negligible sales; heavy convertible debt and going concern

REMSLEEP HOLDINGS, INC. (PINK: RMSL) - Quick read on what's happening inside

Snapshot - key figures (as reported)
* Revenue (Q2 2025): $4,824 ; Revenue (six months 2025): $4,824
* Cost of goods sold (Q2 2025): $600 ; Gross margin (Q2 2025): $4,224
* Loss from operations (Q2 2025): $(132,552)
* Net loss (Q2 2025): $(287,772) ; Net loss (six months 2025): $(373,260)
* Total assets (June 30, 2025): $541,714 ; Cash: $415,975 (down from $463,343 at 12/31/24)
* Total liabilities: $401,708 ; Derivative liability: $191,306
* Convertible notes payable, net: $107,590 ; Debt discount to be amortized (non‑cash disclosure): $364,934
* Inventory (June 30, 2025): $19,835 ; Accumulated deficit: $(15,644,016)
* Shares outstanding (Aug 14, 2025): 1,560,979,765 ; Weighted average shares (Q2): 1,544,085,007

What's happening inside the company
* Product pivot and commercialization: Company received FDA 510(k) approval for the DeltaWave on July 2, 2024 and began selling DeltaWave products and building inventory in Q2 2025. Revenue is modest so far ($4,824 for the period).
* Cost control where possible: Development, professional fees and lease expenses materially declined year‑over‑year (development expense down sharply after product completion).
* Heavy reliance on convertible debt: Multiple 10% convertible notes issued in late 2024/2025 (many to 1800 Diagonal/related entities). Several notes converted to common stock (22,460,270 shares from conversion during the six months); debt discounts are significant and drive non‑cash interest amortization.
* Governance/operations: Management flagged ineffective disclosure controls due to lack of segregation of duties. Related‑party activity (compensation, loans, vendor payments) is disclosed.

Positive aspects of the income statement and operations
* Gross margin on sales is positive: DeltaWave gross margin reported at $4,224 for the period (sales exceeded direct COGS).
* Lower operating expense run‑rate in 2025 vs prior year: Professional fees, development and lease expense all declined materially, helping to reduce operating losses versus certain prior periods.
* Non‑cash derivative gains helped offset some financing charges: Change in fair value of derivatives produced a gain of $75,335 in Q2 and $283,361 for six months, partially offsetting financing losses.

Negative aspects of the income statement and risks
* Revenue is negligible and not yet recurring: $4,824 in revenue for six months of 2025 - product commercialization has started but sales traction is extremely limited.
* Large financing costs driven by debt discounts: Interest expense (largely amortization of debt discounts) was $143,635 in Q2 and $219,967 for six months - this amplifies losses despite low operating cash needs.
* Substantial dilution risk: Large outstanding common share base (1.56B) plus potentially dilutive preferred and convertible instruments (documented potential dilutive shares include Series A, B, C and convertible debt).
* Going concern: Management discloses substantial doubt about the company's ability to continue as a going concern - cumulative losses, negative operating cash flow and uncertain ability to raise capital are explicit concerns.
* Balance sheet and liquidity constraints: Cash declined to $415,975 and operating cash used was $(251,368) for six months; financing inflows ($204,000) partially covered burn. Derivative liability ($191,306) and convertible note net balances create financial complexity.

Operational and financing callouts investors should note
* FDA 510(k) and product: DeltaWave approval (7/2/2024) is the primary strategic asset - commercialization execution will drive future revenue or demonstrate that product-market fit is limited.
* Rapid share issuance and conversions: The company issued shares for debt conversions and earlier warrant exercises - continuing conversions and future financing could further dilute shareholders.
* Related‑party concentration: Multiple financings and service payments involve related parties (1800 Diagonal, CEO family payments, accrued compensation to former chairman), which increases governance and conflict‑of‑interest scrutiny.
* Lease and footprint changes: Prior lease terminated Feb 2025; new smaller lease commenced June 1, 2025 (right‑of‑use asset $35,022 and related lease liability $35,022).

Bottom line (straightforward)
* REMSLEEP HOLDINGS, INC. (PINK: RMSL) has a validated product (DeltaWave) but minimal current revenue and continued operating losses. Management has reduced some operating costs, yet the company remains dependent on convertible debt and equity financing. Significant dilution risk, meaningful non‑cash financing charges and a disclosed going‑concern raise material execution and financing risks. Short term outlook depends on ramping DeltaWave sales or securing new financing on acceptable terms.

Data sourced directly from the company's Form 10‑Q for the quarter ended June 30, 2025 (filed Aug 14, 2025).